January 2, 2019 07:02 AM EST

New Year’s Day price hikes on blockbuster drugs set the stage for a big debate

Allergan, Pfizer, Bristol-Myers Squibb, Biogen and other top drugmakers all celebrated the New Year’s with a traditional boost in the price of their top drugs.

For Allergan, there was an across-the-board hike of 9.5% for 7 of its top 10 products. Biogen’s Tecfidera went up 6%, according to a roster of new drug prices assembled January 1 by Umer Raffat from Evercore ISI. Jardiance and Tradjenta at Eli Lilly went up 6% — after they triggered a 2% hike for Alimta just before New Year’s. And so on….

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE

TRENDING NOW

New Year’s Day price hikes on blockbuster drugs set the stage for a big debate

This article is for premium subscribers only

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Adcomm recommends FDA reject BrainStorm's ALS drug after company filed over protest

Biogen’s R&D pruning hits digital health as biotech scraps 23,000-person cognitive study with Apple

Data Quality 2.0: The Future of Real-World Evidence

New Year’s Day price hikes on block­buster drugs set the stage for a big de­bate

This article is for premium subscribers only

J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

Stephen Hahn’s liq­uid biop­sy com­pa­ny Har­bin­ger Health rais­es $140M Se­ries B to launch first can­cer tests by 2025

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

Ad­comm rec­om­mends FDA re­ject Brain­Stor­m's ALS drug af­ter com­pa­ny filed over protest

Bio­gen’s R&D prun­ing hits dig­i­tal health as biotech scraps 23,000-per­son cog­ni­tive study with Ap­ple

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

New Year’s Day price hikes on blockbuster drugs set the stage for a big debate

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Adcomm recommends FDA reject BrainStorm's ALS drug after company filed over protest

Biogen’s R&D pruning hits digital health as biotech scraps 23,000-person cognitive study with Apple

Data Quality 2.0: The Future of Real-World Evidence